Spyre Therapeutics Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/18/2026)
| Balance Sheet | Total Assets | 777,781,000.00 | ROE | 91.96 % |
| Balance Sheet | Total Equity | 715,236,000.00 | ROA | -19.95 % |
| Cashflow | Capital Expenditures | -1.00 | P/FCF | -36.32 |
| Cashflow | Free Cash Flow | -169,252,000.00 | – | – |
| Cashflow | Operating Cash Flow | -169,252,000.00 | P/CF | -36.32 |
| Income | Earnings per Share (diluted) | -36.15 | Div. Yield | – |
| Income | Net Income | -126,541,000.00 | P/E | -39.71 |
| Income | Shares Outstanding | 78,189,811.00 | P/B | 8.60 |
| Income | Total Revenue | 1,000.00 | P/S | 1,000,000.00 |
Ratios calculated on: 10/14/2026
Company Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.aegleabio.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more